A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy

Chimeric antigen receptor (CAR) T cells targeting CD19 have been successful treating patients with relapsed/refractory B cell acute lymphoblastic leukemia (ALL) and B cell lymphomas. However, relapse after CAR T cell therapy is still a challenge. In addition, preclinical and early clinical studies t...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Rebecca Epperly, Stephen Gottschalk, M. Paulina Velasquez
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2020-02-01
coleção:	Frontiers in Oncology
Assuntos:	chimeric antigen receptor cellular therapy immunotherapy acute myeloid leukemia microenvironment
Acesso em linha:	https://www.frontiersin.org/article/10.3389/fonc.2020.00262/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!